newsfilter
← Latest News
Business Wire·

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Novel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following intravenous